NBP24527802
Macrophage and Histiocytoma Marker Antibody (D11), Novus Biologicals™
Manufacturer: Fischer Scientific
The price for this product is unavailable. Please request a quote
Antigen
Macrophage and Histiocytoma Marker
Classification
Monoclonal
Concentration
0.2mg/mL
Dilution
Immunohistochemistry-Paraffin 0.5 - 1.0 ug/ml
Host Species
Mouse
Purification Method
Protein A or G purified
Regulatory Status
RUO
Test Specificity
In Western blotting, it detects an antigen of 125kDa in human liver and 135kDa in tumors of histiocytic origin. Comparative study of this MAb and a standard CD68 MAb showed that their antigens are different. Its antigen in all macrophage types studied is located on the plasma membrane and within cytoplasmic structures including lysosomes. This MAb shows a restricted reactivity to cells of the monocyte/macrophage system. It specifically reacts with blood monocytes and stains resident macrophages in a wide variety of human tissues. This MAb does not stain antigen-presenting cells, e.g., Langerhans cells. Reportedly, its reactivity is restricted to histiocytes and macrophages.
Content And Storage
Store at 4C.
Isotype
IgG1 κ
Applications
Immunohistochemistry (Paraffin)
Clone
D11
Conjugate
Unconjugated
Formulation
10mM PBS with 0.05% Sodium Azide
Immunogen
Membrane preparation from human hepatocytes
Quantity
0.2 mg
Primary or Secondary
Primary
Target Species
Human, Mouse (Negative), Porcine (Negative), Rat (Negative)
Form
Purified
Related Products
Description
- Ensure accurate, reproducible results in Immunohistochemistry (Paraffin) Macrophage and Histiocytoma Marker Monoclonal specifically detects Macrophage and Histiocytoma Marker in Human, Mouse (Negative), Porcine (Negative), Rat (Negative) samples
- It is validated for Immunohistochemistry, Immunohistochemistry-Paraffin.
Compare Similar Items
Show Difference
Antigen: Macrophage and Histiocytoma Marker
Classification: Monoclonal
Concentration: 0.2mg/mL
Dilution: Immunohistochemistry-Paraffin 0.5 - 1.0 ug/ml
Host Species: Mouse
Purification Method: Protein A or G purified
Regulatory Status: RUO
Test Specificity: In Western blotting, it detects an antigen of 125kDa in human liver and 135kDa in tumors of histiocytic origin. Comparative study of this MAb and a standard CD68 MAb showed that their antigens are different. Its antigen in all macrophage types studied is located on the plasma membrane and within cytoplasmic structures including lysosomes. This MAb shows a restricted reactivity to cells of the monocyte/macrophage system. It specifically reacts with blood monocytes and stains resident macrophages in a wide variety of human tissues. This MAb does not stain antigen-presenting cells, e.g., Langerhans cells. Reportedly, its reactivity is restricted to histiocytes and macrophages.
Content And Storage: Store at 4C.
Isotype: IgG1 κ
Applications: Immunohistochemistry (Paraffin)
Clone: D11
Conjugate: Unconjugated
Formulation: 10mM PBS with 0.05% Sodium Azide
Immunogen: Membrane preparation from human hepatocytes
Quantity: 0.2 mg
Primary or Secondary: Primary
Target Species: Human, Mouse (Negative), Porcine (Negative), Rat (Negative)
Form: Purified
Antigen:
Macrophage and Histiocytoma Marker
Classification:
Monoclonal
Concentration:
0.2mg/mL
Dilution:
Immunohistochemistry-Paraffin 0.5 - 1.0 ug/ml
Host Species:
Mouse
Purification Method:
Protein A or G purified
Regulatory Status:
RUO
Test Specificity:
In Western blotting, it detects an antigen of 125kDa in human liver and 135kDa in tumors of histiocytic origin. Comparative study of this MAb and a standard CD68 MAb showed that their antigens are different. Its antigen in all macrophage types studied is located on the plasma membrane and within cytoplasmic structures including lysosomes. This MAb shows a restricted reactivity to cells of the monocyte/macrophage system. It specifically reacts with blood monocytes and stains resident macrophages in a wide variety of human tissues. This MAb does not stain antigen-presenting cells, e.g., Langerhans cells. Reportedly, its reactivity is restricted to histiocytes and macrophages.
Content And Storage:
Store at 4C.
Isotype:
IgG1 κ
Applications:
Immunohistochemistry (Paraffin)
Clone:
D11
Conjugate:
Unconjugated
Formulation:
10mM PBS with 0.05% Sodium Azide
Immunogen:
Membrane preparation from human hepatocytes
Quantity:
0.2 mg
Primary or Secondary:
Primary
Target Species:
Human, Mouse (Negative), Porcine (Negative), Rat (Negative)
Form:
Purified
Antigen: CDw17
Classification: Monoclonal
Concentration: 0.2 mg/mL
Dilution: Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunofluorescence 0.5 - 1.0 ug/ml
Host Species: Mouse
Purification Method: Protein A or G purified
Regulatory Status: RUO
Test Specificity: CD17 is an intermediate glycosphingolipid from the metabolism of higher gangliosides that localizes to sphingolipid-sterol rafts. CD17 is detectable in monocytes, granulocytes, basophils, platelets, a subset of peripheral B cells (CD19+) and tonsil dendritic cells. It is rapidly down regulated on activated granulocytes and is upregulated on IL-2 activated T lymphocytes. CD17 binds to bacteria and may function in phagocytosis. VEGF-treated endothelial cells can produce CD17, which can then mediate signaling toward PECAM-1 expression and angiogenesis. Tumor necrosis factor alpha (TNFalpha)-induced astrogliosis (astrocyte proliferation and glial fibrillary acidic protein (GFAP) upregulation) in response to neuro-inflammation (i.e. spinal cord injury) causes an increase in intracellular levels of CD17. Aberrant levels of glycosphingolipids are a feature of cancer cells and may influence integrin clustering and internalization.
Content And Storage: Store at 4C.
Isotype: IgM
Applications: Flow Cytometry, Immunofluorescence
Clone: HO18.3G-6.F5
Conjugate: Unconjugated
Formulation: 10mM PBS and 0.05% BSA with 0.05% Sodium Azide
Immunogen: B-2 Microglobulin associated proteins from a detergent lysate of human PBL
Quantity: 0.02 mg
Primary or Secondary: Primary
Target Species: Human
Form: Purified
Antigen:
CDw17
Classification:
Monoclonal
Concentration:
0.2 mg/mL
Dilution:
Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunofluorescence 0.5 - 1.0 ug/ml
Host Species:
Mouse
Purification Method:
Protein A or G purified
Regulatory Status:
RUO
Test Specificity:
CD17 is an intermediate glycosphingolipid from the metabolism of higher gangliosides that localizes to sphingolipid-sterol rafts. CD17 is detectable in monocytes, granulocytes, basophils, platelets, a subset of peripheral B cells (CD19+) and tonsil dendritic cells. It is rapidly down regulated on activated granulocytes and is upregulated on IL-2 activated T lymphocytes. CD17 binds to bacteria and may function in phagocytosis. VEGF-treated endothelial cells can produce CD17, which can then mediate signaling toward PECAM-1 expression and angiogenesis. Tumor necrosis factor alpha (TNFalpha)-induced astrogliosis (astrocyte proliferation and glial fibrillary acidic protein (GFAP) upregulation) in response to neuro-inflammation (i.e. spinal cord injury) causes an increase in intracellular levels of CD17. Aberrant levels of glycosphingolipids are a feature of cancer cells and may influence integrin clustering and internalization.
Content And Storage:
Store at 4C.
Isotype:
IgM
Applications:
Flow Cytometry, Immunofluorescence
Clone:
HO18.3G-6.F5
Conjugate:
Unconjugated
Formulation:
10mM PBS and 0.05% BSA with 0.05% Sodium Azide
Immunogen:
B-2 Microglobulin associated proteins from a detergent lysate of human PBL
Quantity:
0.02 mg
Primary or Secondary:
Primary
Target Species:
Human
Form:
Purified
Antigen: CDw17
Classification: Monoclonal
Concentration: 0.2 mg/mL
Dilution: Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunofluorescence 0.5 - 1.0 ug/ml
Host Species: Mouse
Purification Method: Protein A or G purified
Regulatory Status: RUO
Test Specificity: CD17 is an intermediate glycosphingolipid from the metabolism of higher gangliosides that localizes to sphingolipid-sterol rafts. CD17 is detectable in monocytes, granulocytes, basophils, platelets, a subset of peripheral B cells (CD19+) and tonsil dendritic cells. It is rapidly down regulated on activated granulocytes and is upregulated on IL-2 activated T lymphocytes. CD17 binds to bacteria and may function in phagocytosis. VEGF-treated endothelial cells can produce CD17, which can then mediate signaling toward PECAM-1 expression and angiogenesis. Tumor necrosis factor alpha (TNFalpha)-induced astrogliosis (astrocyte proliferation and glial fibrillary acidic protein (GFAP) upregulation) in response to neuro-inflammation (i.e. spinal cord injury) causes an increase in intracellular levels of CD17. Aberrant levels of glycosphingolipids are a feature of cancer cells and may influence integrin clustering and internalization.
Content And Storage: Store at 4C.
Isotype: IgM
Applications: Flow Cytometry, Immunofluorescence
Clone: HO18.3G-6.F5
Conjugate: Unconjugated
Formulation: 10mM PBS and 0.05% BSA with 0.05% Sodium Azide
Immunogen: B-2 Microglobulin associated proteins from a detergent lysate of human PBL
Quantity: 0.1 mg
Primary or Secondary: Primary
Target Species: Human
Form: Purified
Antigen:
CDw17
Classification:
Monoclonal
Concentration:
0.2 mg/mL
Dilution:
Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunofluorescence 0.5 - 1.0 ug/ml
Host Species:
Mouse
Purification Method:
Protein A or G purified
Regulatory Status:
RUO
Test Specificity:
CD17 is an intermediate glycosphingolipid from the metabolism of higher gangliosides that localizes to sphingolipid-sterol rafts. CD17 is detectable in monocytes, granulocytes, basophils, platelets, a subset of peripheral B cells (CD19+) and tonsil dendritic cells. It is rapidly down regulated on activated granulocytes and is upregulated on IL-2 activated T lymphocytes. CD17 binds to bacteria and may function in phagocytosis. VEGF-treated endothelial cells can produce CD17, which can then mediate signaling toward PECAM-1 expression and angiogenesis. Tumor necrosis factor alpha (TNFalpha)-induced astrogliosis (astrocyte proliferation and glial fibrillary acidic protein (GFAP) upregulation) in response to neuro-inflammation (i.e. spinal cord injury) causes an increase in intracellular levels of CD17. Aberrant levels of glycosphingolipids are a feature of cancer cells and may influence integrin clustering and internalization.
Content And Storage:
Store at 4C.
Isotype:
IgM
Applications:
Flow Cytometry, Immunofluorescence
Clone:
HO18.3G-6.F5
Conjugate:
Unconjugated
Formulation:
10mM PBS and 0.05% BSA with 0.05% Sodium Azide
Immunogen:
B-2 Microglobulin associated proteins from a detergent lysate of human PBL
Quantity:
0.1 mg
Primary or Secondary:
Primary
Target Species:
Human
Form:
Purified
Antigen: CDw17
Classification: Monoclonal
Concentration: 0.2 mg/mL
Dilution: Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunofluorescence 0.5 - 1.0 ug/ml
Host Species: Mouse
Purification Method: Protein A or G purified
Regulatory Status: RUO
Test Specificity: CD17 is an intermediate glycosphingolipid from the metabolism of higher gangliosides that localizes to sphingolipid-sterol rafts. CD17 is detectable in monocytes, granulocytes, basophils, platelets, a subset of peripheral B cells (CD19+) and tonsil dendritic cells. It is rapidly down regulated on activated granulocytes and is upregulated on IL-2 activated T lymphocytes. CD17 binds to bacteria and may function in phagocytosis. VEGF-treated endothelial cells can produce CD17, which can then mediate signaling toward PECAM-1 expression and angiogenesis. Tumor necrosis factor alpha (TNFalpha)-induced astrogliosis (astrocyte proliferation and glial fibrillary acidic protein (GFAP) upregulation) in response to neuro-inflammation (i.e. spinal cord injury) causes an increase in intracellular levels of CD17. Aberrant levels of glycosphingolipids are a feature of cancer cells and may influence integrin clustering and internalization.
Content And Storage: Store at 4C.
Isotype: IgM
Applications: Flow Cytometry, Immunofluorescence
Clone: HO18.3G-6.F5
Conjugate: Unconjugated
Formulation: 10mM PBS and 0.05% BSA with 0.05% Sodium Azide
Immunogen: B-2 Microglobulin associated proteins from a detergent lysate of human PBL
Quantity: 0.2 mg
Primary or Secondary: Primary
Target Species: Human
Form: Purified
Antigen:
CDw17
Classification:
Monoclonal
Concentration:
0.2 mg/mL
Dilution:
Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunofluorescence 0.5 - 1.0 ug/ml
Host Species:
Mouse
Purification Method:
Protein A or G purified
Regulatory Status:
RUO
Test Specificity:
CD17 is an intermediate glycosphingolipid from the metabolism of higher gangliosides that localizes to sphingolipid-sterol rafts. CD17 is detectable in monocytes, granulocytes, basophils, platelets, a subset of peripheral B cells (CD19+) and tonsil dendritic cells. It is rapidly down regulated on activated granulocytes and is upregulated on IL-2 activated T lymphocytes. CD17 binds to bacteria and may function in phagocytosis. VEGF-treated endothelial cells can produce CD17, which can then mediate signaling toward PECAM-1 expression and angiogenesis. Tumor necrosis factor alpha (TNFalpha)-induced astrogliosis (astrocyte proliferation and glial fibrillary acidic protein (GFAP) upregulation) in response to neuro-inflammation (i.e. spinal cord injury) causes an increase in intracellular levels of CD17. Aberrant levels of glycosphingolipids are a feature of cancer cells and may influence integrin clustering and internalization.
Content And Storage:
Store at 4C.
Isotype:
IgM
Applications:
Flow Cytometry, Immunofluorescence
Clone:
HO18.3G-6.F5
Conjugate:
Unconjugated
Formulation:
10mM PBS and 0.05% BSA with 0.05% Sodium Azide
Immunogen:
B-2 Microglobulin associated proteins from a detergent lysate of human PBL
Quantity:
0.2 mg
Primary or Secondary:
Primary
Target Species:
Human
Form:
Purified